Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships by Leven, Cyril et al.
HAL Id: hal-02179154
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02179154
Submitted on 16 Sep 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Immune Checkpoint Inhibitors in Melanoma: A Review
of Pharmacokinetics and Exposure-Response
Relationships
Cyril Leven, Maël Padelli, Jean-Luc Carré, Éric Bellissant, Laurent Misery
To cite this version:
Cyril Leven, Maël Padelli, Jean-Luc Carré, Éric Bellissant, Laurent Misery. Immune Checkpoint
Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships. Clin-
ical Pharmacokinetics, Springer Verlag, 2019, 58 (11), pp.1393-1405. ￿10.1007/s40262-019-00789-7￿.
￿hal-02179154￿
1 
 
Immune Checkpoint Inhibitors in Melanoma: A Review of 
Pharmacokinetics and Exposure-Response Relationships 
 
Cyril Leven1,2, Maël Padelli1,2, Jean-Luc Carré 1,2, Eric Bellissant3,4,5, Laurent Misery2,6 
 
1. Department of Biochemistry and Pharmaco-Toxicology, Brest University Hospital, Brest, France 
2. Univ Brest, LIEN, Brest, France 
3. Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmaco-
epidemiology and Drug Information Centre, Rennes University Hospital, Rennes, France 
4. Laboratory of Experimental and Clinical Pharmacology, Faculty of Medicine, Rennes 1 University, 
Rennes, France 
5. Clinical Investigation Centre, CIC Inserm 1414, Rennes, France 
6. Department of Dermatology, Brest University Hospital, Brest, France 
 
Corresponding author: 
Cyril Leven 
ORCID: 0000-0002-0697-4370 
cyril.leven@chu-brest.fr 
+33612916167 (France) 
 
Word count: 6234 
Running heading: Pharmacokinetics and Exposure-Response Relationships of Immune Checkpoint 
Inhibitors in Melanoma   
Ac
ce
pte
d m
nu
cri
pt
2 
 
Abstract 
Immune checkpoint inhibitors are a new class of monoclonal antibodies that amplify T-cell-mediated 
immune responses against cancer cells. The introduction of these new drugs, first anti-CTLA4 and then 
anti-PD1, was a major advance in the treatment of advanced or metastatic melanoma, a highly 
immunogenic tumor. The development strategy for immune checkpoint immunotherapies differed 
from that traditionally used for cytotoxic therapies in oncology. The choices of doses at which to 
conduct clinical trials and subsequently the choices of doses at which to use these new therapies were 
not based on the identification of a maximum tolerated dose from dose escalation studies. Thus, 
pharmacokinetic and pharmacokinetic-pharmacodynamic modelling was essential. The studies 
conducted have shown that the pharmacokinetics of ipilimumab was linear and not time-dependent. 
In addition, there was a correlation between the trough concentrations of ipilimumab and its 
therapeutic efficacy. On the contrary, the anti-PD1 immunotherapies nivolumab and pembrolizumab 
had a time-dependent pharmacokinetics. Their therapeutic efficacy was not related to their trough 
concentration, but there was a correlation between the clearance of anti-PD1 and the survival of 
melanoma patients. This review highlights the complexity of interpreting the exposure-response 
relationships of these agents. Further studies will be needed to assess the value of therapeutic drug 
monitoring of immune checkpoint inhibitors in the treatment of melanoma. 
 
Key Points 
 Immune checkpoint inhibitors are a new class of anti-cancer drugs; the characterization of their 
exposure-response relationships is still ongoing. 
 The steady state minimum concentrations of anti-CTLA4 ipilimumab are correlated with its 
therapeutic efficacy, but a range of optimal concentrations to maximize therapeutic efficacy and 
tolerability has not yet been identified. 
Ac
ce
pte
d m
an
us
cri
3 
 
 No correlation was found between exposure to the anti-PD1 pembrolizumab and nivolumab and 
their therapeutic efficacy and tolerability for the doses studied in the clinical trials. However, the 
clearances of anti-PD1 are correlated with the survival rates of melanoma patients. 
 
1. Introduction 
The incidence of skin melanoma is growing faster than that of any other solid tumour: 160,000 new 
cases and 48,000 deaths occur each year worldwide [1]. Melanoma develops a complex interaction 
with the immune system, highlighted by several observations: melanoma antigens are recognized by 
T cells [2], immune infiltrations in primary tumours have a strong prognostic importance [3], 
spontaneous regression is sometimes observed in metastatic patients [4], and vitiligo may be 
associated with regression of metastatic lesions under treatment [5,6]. 
Immune checkpoint inhibitors are a new class of immunotherapies whose discovery was recently 
(2018) awarded a Nobel Prize in medicine. Drugs targeting the cutaneous T lymphocyte antigen-4 
(CTLA-4) or the programmed death-1 (PD-1) receptor represent a major advance in the treatment of 
advanced or metastatic melanoma. Indeed, to prevent auto-immunity, several signalling pathway 
control points regulate T cell activity at different steps of the immune response in a process called 
peripheral tolerance. The CTLA-4 and PD-1 control points are at the heart of this process: CTLA-4 is 
currently considered as the leader of immune check point inhibition because it intercepts self-reactive 
cells at the initial step of T cell activation, typically in the lymph nodes [7,8], and the PD-1 receptor 
pathway regulates already active T cells at later steps of immune response, primarily in peripheral 
tissues [7]. In fact, PD-1 expression is the characteristic sign of "exhausted" T cells that have 
experienced significant levels of stimulation or reduced CD4+ T cell aid [9]. A high level of PD-1 
expression is found in non-functional T cells in the context of chronic infection [10] or of tumour 
progression [11]. 
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The distribution of PD-1 ligands differs from those of CTLA-4, which has direct consequences on the 
efficacy and tolerability profile of the various immune check point inhibitors monoclonal antibodies 
used in oncology. Unlike anti-CTLA-4, PD-1/PD-L1 (Programmed death-ligand 1) interaction occurs 
more selectively at the level of the tumour microenvironment, regulating the effective phase of the T 
cell response, making it a more attractive control point to target. In humans, the small lymphocyte 
sub-population affected by PD-1 blockade compared to that affected by CTLA-4 blockade may explain 
the lower incidence of adverse events (AE) seen to date with anti-PD1 versus anti-CTLA-4 [12]. 
The indications for immune checkpoint inhibitors authorized in the treatment of melanoma differ 
according to their target antigen. Anti-PD1 immunotherapy is recommended as the first-line treatment 
for advanced non-resectable or metastatic melanoma, regardless of BRAF V600 status, and is indicated 
as the second-line treatment for BRAF V600 mutated patients after failure of targeted anti-BRAF and 
anti-MEK combination therapies [13,14]. Anti-CTLA4 immunotherapy is indicated in the first line in 
combination with anti-PD1, as well as monotherapy in the second line of treatment after failure of 
anti-PD1 treatment. Anti-PD1 and anti-CTLA4 are also indicated in the adjuvant treatment of 
melanoma after surgical resection, although in view of its toxicity the use of an anti-CTLA4 in adjuvant 
therapy is controversial [15]. 
The purpose of this review is to present and analyse currently available pharmacokinetic (PK) and 
pharmacodynamic (PD) data of new immune checkpoint inhibitors developed in skin melanoma to 
identify the doses and schedules of administration that optimize the best efficacy/tolerance ratio. 
 
2. Structure of monoclonal antibodies 
2.1. Approved monoclonal antibodies 
Immune checkpoint inhibitors currently approved in Europe and in the United States of America for 
the treatment of advanced or metastatic melanoma are ipilimumab (Yervoy®, Bristol-Myers Squibb) 
[16], an anti CTLA-4, and pembrolizumab (Keytruda®, Merck) [17] and nivolumab (Opdivo®, Bristol-
Ac
ce
pt
d m
an
sc
rip
t
5 
 
Myers Squibb) [18], both anti-PD-1 (Table 1). Other anti-PD-1, like cemiplimab (Libtayo®, Sanofi-
Regeneron) currently approved in the USA for the treatment of patients with metastatic cutaneous 
squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not 
candidates for curative surgery or curative radiation [19], will follow. 
Ipilimumab is a fully human IgG1kappa monoclonal antibody directed against the CTLA-4 protein [20]. 
Pembrolizumab is a humanized IgG4 monoclonal antibody directed against the PD-1 receptor [21,22]. 
Nivolumab is a fully human IgG4 monoclonal antibody also directed against the PD-1 receptor [23,24]. 
2.2. Other molecules 
A few small molecules PD-1/PD-L1 inhibitors have also been described so far: peptidic direct PD-1 
antagonists, small molecule PD-L1 dimerizer and small molecules whose mode-of-action remains 
unknown [25], but most of them have only modest inhibitory activity [26]. 
Monoclonal antibodies are very specific to their targets and provide a long-lasting effect, but they also 
have certain disadvantages in the context of immunotherapy. Their large size makes it difficult to 
access exhausted intratumoral T cells (at least for anti-PD1) and the use of antibodies can be 
challenging to treat tumours located at immune privileged sites such as the eye or the brain [27,28]. 
In addition, the intravenous route of administration requires the patients to come to the hospital. An 
increasing number of monoclonal antibodies are administered subcutaneously, providing a better 
quality of life for patients and reducing the economic burden of treatment [29]. These limitations 
provide arguments for the development of non-monoclonal antibodies immune checkpoint inhibitors, 
but these drug candidates are outside the scope of this review. 
 
3. Pharmacokinetics 
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3.1. Ipilimumab 
The PK of ipilimumab has not been evaluated in healthy volunteers, the majority of available data 
coming from patients with advanced melanoma. 
The PK of ipilimumab was studied by population approach (popPK) following a phase II randomized 
controlled dose escalation clinical trial: CA184-022 (Table 2) [30]. This analysis provided the 
information submitted to the European Medicines Agency for the approval of ipilimumab [20,31].  
Modelling results showed a linear, non-time dependent (time-invariant) PK for the dose range 
considered (0.3 to 10 mg/kg). Plasma ipilimumab concentration-time data were satisfactorily 
described by a bi-compartimental model, with zero order intravenous (IV) infusion and first order 
elimination. After IV administration, ipilimumab followed biphasic elimination with a distribution half-
life of 27.4 h and a slow elimination with an average half-life of 14.7 days. The clearance averaged 0.36 
L/day (normalized to a 80 kg body weight). Peripheral (Vp) and central compartment volumes (Vc) 
were estimated at 4.15 L and 3.11 L respectively (normalized to a 80 kg body weight). 
Weight at baseline was the most influential covariate on clearance and Vc, which was consistent with 
the non-specific monoclonal antibody removal mechanism mediated by the reticulo-endothelial 
system [32,33]. The effects of other covariates were within ± 20% which led the authors to consider 
them as not-clinically significant. A 22% increase in clearance was estimated due to anti-ipilimumab 
antibodies (ADA, anti-drug antibody) but was not considered as clinically significant by the authors as 
less than 5% of patients had developed ADAs and most of them were transient. Only weight at baseline 
and lactate dehydrogenase (LDH) concentration were retained as covariates in the final model. 
3.2. Pembrolizumab 
The PK of pembrolizumab was first described with a time-invariant model that provided the 
information found in the KEYTRUDA monograph. The modelling proposed by Ahamadi et al. in 2017 
with pembrolizumab was performed from data obtained at doses ranging from 1 to 10 mg/kg 
administered intra-venously [34]. Most of the patients were treated for melanoma or non-small cell 
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lung cancer (NSCLC) but several other tumour types were found in the first-in-human dose escalation 
study KEYNOTE-001 (Table 2). 
PK of pembrolizumab was well described by a bicompartimental model with linear clearance. A non-
linear PK was observed for pembrolizumab at doses well below 1 mg/kg [35]. However, a trend to 
increasing concentrations beyond week-20 was detected which may indicate a contribution of time to 
the value of PK parameters. The estimated elimination half-life was 27.3 days. The clearance was low 
(0.22 L/day) and the volume of distribution was estimated at approximately 6 L, a result compatible 
with limited distribution outside the extracellular space. The effects of albumin at baseline, sex, and 
history of ipilimumab treatment on VC were retained in the final model. The effects of albumin and 
tumour load at baseline, glomerular filtration rate, sex, tumour type, Eastern Cooperative Oncology 
Group Performance Status (ECOG-PS) score at baseline, and ipilimumab treatment history on clearance 
were also retained in the final model. The ECOG-PS score is the standard criterion for measuring how 
the disease impacts a patient’s daily living abilities in terms of his ability to care for himself, daily 
activity, and physical ability. Grade 0 translates to a fully active patient, able to carry on all pre-disease 
performance without restriction, while grade 5 is death. 
The time-dependent PK hypothesis led to a new popPK analysis [36] (Table 2). Several covariates were 
retained in the time-dependent model. Pembrolizumab clearance was associated with low albumin 
levels, greater tumour size at baseline and a higher ECOG-PS score. Systemic inflammation, cachexia 
and a target mediated drug disposition (TMDD) component of elimination were among the hypotheses 
put forward by the authors to explain these observations. 
The median population clearance value was approximately 20% lower at steady state compared to 
clearance at first administration. According to authors, this decrease of clearance should not have 
clinical consequences because variations in exposure by a factor of 5 were observed in clinical trials 
without any consequence on efficacy or safety of pembrolizumab. 
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3.3. Nivolumab 
The PK of nivolumab was studied using a popPK approach using data from 1,895 patients from 3 Phase 
I studies, 3 Phase II studies, and 5 Phase III studies [37] (Table 2). Most patients were treated for 
melanoma or NSCLC but several other tumour types were found in these studies. 
Patients received nivolumab at doses ranging from 0.1 to 10 mg/kg in single administrations every 2 
weeks or every 3 weeks depending on the study. The majority of patients received nivolumab at 3 
mg/kg every 2 weeks. 
The PK of nivolumab was described as linear with a dose-independent clearance from 0.1 to 20 mg/kg. 
The authors did not present any external validation of their model. The inclusion of a TMDD 
component in the elimination did not improve the model. The selected model was a bicompartmental 
model with zero order IV administration and first order elimination. The PK of nivolumab was initially 
modelled with invariant clearance, it was later reassessed based on findings with pembrolizumab. 
In the final model, clearance decreased over time, with a maximum change from baseline of about 
24.5%. The time-dependent component of nivolumab clearance was described by a sigmoid 
relationship. Based on the results of this analysis, nivolumab followed biphasic elimination after IV 
administration consisting of a rapid distribution phase with a half-life of 32.5 hours and a slow 
elimination phase with an average half-life of 25 days at steady state. The average clearance was 
estimated at 0.226 L/day (normalized to a 80 kg weight), the Vc and Vp were estimated at 3.63 L and 
2.78 L respectively (normalized to a 80 kg, white female). 
The FDA analysis revealed that the clearance of nivolumab decreases as the disease status improves 
[38]: the change in clearance of nivolumab is correlated with the post-treatment ECOG-PS score and is 
not only time-dependent. By studying patient data from the Bajaj et al. study [37], it was shown that 
patients with better status and higher survival had a greater reduction in nivolumab clearance 
compared to their clearance at baseline. This reduction resulted in significantly greater steady state 
exposure than with the first administration of nivolumab. 
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4. Pharmacodynamics 
4.1. Ipilimumab 
A Phase 2 randomized controlled exploratory study that studied the impact of ipilimumab on tumour 
microenvironment showed an increase in T cell activation marker expression [39]. The mean levels of 
activated (HLA-DR+), CD4 and CD8 peripheral blood activated T cells were increased after ipilimumab 
administration. No differences in activation were observed between 3 mg/kg and 10 mg/kg doses. 
These results were consistent with a dose escalation study conducted in 46 patients with metastatic 
melanoma (stage IV) [40]. 
The absolute lymphocyte count, a measure of all circulating B and T lymphocytes, was positively 
associated with overall survival (OS) in melanoma in therapeutic trials with ipilimumab [41]. Several 
studies also showed  an increase in the absolute number of circulating lymphocytes qualified as a 
pharmacodynamic marker of immune cell activation by ipilimumab at doses of 3 and 10 mg/kg 
[30,39,41]. The absolute number of lymphocytes increased in a dose-dependent manner and 
continued to increase during the induction period. 
Study CA184-022 was a randomized controlled Phase II dose-escalation clinical trial (Table 3). 
Ipilimumab showed a dose-dependent effect on OS. Favourable albeit non-significant results were 
noted in favour of the 10 mg/kg dose both in terms of response and OS. Similarly, the incidence of 
immune related adverse events (irAE) of any grade increased with increasing doses of ipilimumab. No 
grade 4 toxicity was found and no grade 3-4 toxicity occurred for 0.3 mg/kg. The most common cause 
of treatment interruption or death was disease progression. 
The exposure-response (E-R) relationship of ipilimumab in patients with advanced (unresectable or 
metastatic) melanoma was evaluated in a retrospective study [42] (Table 3). The steady state minimum 
concentration (Cminss) at the end of the induction phase (4 doses spaced 3 weeks apart) was a 
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statistically significant predictor of response and there was a statistically significant relationship 
between ipilimumab exposure and the hazard ratio of death. 
The exposure-response analysis for tolerability showed that the probability of having an irAE of grade 
2 or higher, grade 3 or higher, and the probability of a first irAE occurring at any time increased with 
Cminss over the studied dose range. 
Given the association observed between Cminss and both therapeutic efficacy and tolerability, dose 
individualization could be an effective approach for ipilimumab treatment in patients with advanced 
or metastatic melanoma, if a range of optimal concentrations in terms of therapeutic efficacy and 
tolerability is determined. 
4.2. Pembrolizumab 
A first dose-escalation clinical trial involving 13 patients focused on elucidating the pharmacokinetic-
pharmacodynamic (PKPD) relationship by measuring the response in terms of interleukin 2 (IL-2) 
release over a range of 0.005 to 10 mg/kg [43]. The biologically active dose was estimated at 2 mg/kg 
as the simulation results approached saturation at exposures consistent with this dose [44]. 
To determine the lowest effective dose to be used in the Phase I clinical trial KEYNOTE-001, a 
pharmacodynamic study of pembrolizumab was conducted in mice [45]. 
In order to describe the PKPD of pembrolizumab, a complex model was developed from experimental 
mouse data and specific mouse physiological parameters from the literature. For human dose-
response simulations, the model was translated by replacing mouse parameters with human 
parameters where possible and allometrically modifying mouse parameters or keeping them constant 
when the human parameters were unknown. 
 The PK model used in humans was the same as that used in the work of Elassaiss-Schaap et al. [46]. 
Simulations showed that the probability of reaching more than 30% reduction in tumour size reached 
a plateau for doses ≥ 2 mg/kg every 3 weeks. A minor increase in benefit was predicted by 
administration every 2 weeks compared to every 3 weeks. 
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Modelling PD-1 occupancy at the tumour level indicated that PD-1 was saturated at clinically relevant 
concentrations.  
KEYNOTE-001 PKPD data were limited and left uncertainties regarding the linearity of pembrolizumab 
PK and its PD. In order to allow the selection of the lowest dose for future clinical trials, the choice of 
the design of an additional cohort of KEYNOTE-001 (A2) was guided by modelling and simulation results 
[35]. 
Pharmacodynamics was evaluated by measuring the IL2 stimulation ratio in blood, assuming that the 
IL-2 stimulation ratio would be a surrogate marker for pembrolizumab binding to the PD-1 target, a 
reflection of pembrolizumab binding to its target at the tumour level and ultimately a marker of 
pembrolizumab antitumor efficacy. The potency of pembrolizumab (half maximal inhibitory 
concentration) as measured by the IL-2 stimulation ratio test was 0.54 mg/L (95% confidence interval 
0.12-2.3 mg/L). 
The results of the simulations conducted with the consolidated PKPD model (after the introduction of 
the A2 cohort data) showed that target engagement increased monotonously. A dose of 2 mg/kg every 
3 weeks was required to achieve 90% probability of 95%  engagement at steady state [35]. 
To characterize the kinetics of tumour size change during treatment and identify sources of variability 
in response to pembrolizumab, a tumour growth model of melanoma was developed [47] (Table 3). 
The areas under the curve (AUC) for pembrolizumab concentration-time curves were obtained from 
the popPK results [34]. The AUC over 6 weeks at steady state (AUCss6w) was selected as metric to 
account for interdose duration differences. 
The initial model (based on KEYNOTE-001) had to take into account the marked heterogeneity of 
responses. Patients who responded typically showed an early (slow or rapid) decrease in tumour size, 
patients who progressed tended to do so rapidly and to discontinue treatment early. . Tumour growth 
or regression parameters were estimated in a manner comparable to that developed by Claret et al. in 
their model [48,49], modified to account for the many patients in whom tumour size remained stable 
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for long periods after an initial decrease, a different pattern from that observed with conventional 
chemotherapy where relapse is more classic.  
The effect of PD-L1 expression and baseline tumour size on the tumour regression rate, the effect of 
ipilimumab treatment history and tumour size on the proportion of target tumour tissue available for 
treatment, and the effect of BRAF mutation status on the tumor growth rate explained some of the 
inter-individual variability of these parameters. There was overlap in the estimates of these 
parameters between the different groups; the selected covariates being not predictive of response for 
an individual patient. The authors indicated that these results suggested that all patients, regardless 
of their BRAF, PD-1, or ipilimumab treatment history, were likely to benefit from pembrolizumab 
treatment. Exposure characterized by AUCss6w was not a significant predictor of tumour regression. 
The simulations showed a relatively flat exposure-response relationship close to the maximum efficacy 
plateau. Simulations at 1 mg/kg every 3 weeks suggested that patients with a 50% reduction in 
pembrolizumab exposure would maintain therapeutic efficacy. However, the correlation of the 
dynamics of tumour size evolution to survival still needs to be demonstrated. 
Overall, these results suggested that there was no significant exposure-effect relationship for 
pembrolizumab at the doses studied, in favour of an exposure close to the maximum efficacy plateau. 
In addition, the safety profile was similar for all regimens tested in melanoma clinical trials [50,51], and 
a flat E-R relationship was identified for all these regimens in the assessment of irAE events [52]. 
Nevertheless, the time-dependent PK (TDPK) identified by the work of Li et al [36] led to questions 
about the validity of the results of E-R analyses at steady state. Li et al. hypothesized that variations in 
clearance with time could be seen as a sign that effective treatment was reducing the severity of the 
disease. Additional evidence to support this assertion was provided by the association between the 
best overall response (BOR) category of pembrolizumab and the estimated maximum clearance 
change. Decreasing CL during treatment was associated with better outcomes.  The association 
between clearance variation and BOR also led to an association between clearance variation and OS. 
Recently, an E-R analysis studied the exposure-survival relationship of pembrolizumab for the first time 
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[53] using data from KEYNOTE-002 and KEYNOTE-010 studies (Table 3). The findings of the analysis 
were confirmed prospectively with the results of KEYNOTE-024 study. To avoid the pitfall of the 
correlation between clearance and efficacy of pembrolizumab, the exposure measure studied was the 
6-week standardized first-dose AUC. Clearance estimates were derived from the TDPK model [36]. The 
results of this analysis showed that for both dose levels, the median survival of patients with the lowest 
first-dose clearance (1st quartile) was more than doubled compared to patients with the highest first-
dose clearance (4th quartile). There would be no causal relationship between exposure and survival 
and in this context the clearance of anti-PD1 could be an independent marker of disease severity. 
4.3. Nivolumab 
The cohort extension of the Phase Ib open-label dose escalation study (MDX1106-03, NCT00730639) 
[54] involved 306 patients (Table 3). Efficacy endpoints were: objective response rate (ORR), 
progression-free survival rate at 24 weeks (PFS24w). ORR was based on the BOR, evaluated according 
to RECIST v1.1 criteria. 
The dose-response relationship of tolerability was investigated by assessing the correlation between 
grade AEs ≥ 3, AEs leading to discontinuation of treatment and exposure to nivolumab. 
The dose-response relationship of therapeutic efficacy was evaluated in the light of confirmed 
objective responses and tumour growth dynamics. The E-R relationship between ORR and Cminss was 
evaluated by separate logistic regression models for each tumour type among melanomas, NSCLC, 
renal cell cancer. The tumour growth dynamics was characterized using a previously published non-
linear mixed effects model [55]. 
No maximum tolerated dose was identified up to the highest dose studied, 10 mg/kg every 2 weeks. 
Overall, nivolumab was considered safe and tolerable up to this dose. The median duration of 
treatment for all tumour types and doses was 16.1 weeks. 
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The nature, frequency and severity of AEs were comparable across dose levels and tumour types. The 
most common cause of treatment discontinuation was disease progression (n=193, 67.5%). Overall, 
AEs were manageable and reversible with the introduction of immunosuppressants. 
No dose-response relationship was found for AEs at doses studied. In the 69 melanoma patients 
evaluated, the PD-1 occupancy rate on peripheral lymphocytes was saturated at doses ≥ 0.3 mg/kg 
after 8 weeks. But the correlation between peripheral, intratumoral PD-1 binding and cell proliferation 
was not demonstrated. 
The E-R relationship for efficacy was assessed through ORR and tumour growth dynamics (unaffected 
by unconventional responses observed with onco-immunotherapies). A trend was observed between 
high Cminss and ORR, but this effect appeared to plateau at 1 mg/kg in melanoma and 3 mg/kg in 
NSCLC. These results were based on a small number of patients per dose level. 
Exploratory analyses revealed that at a given dose level, responder patients were aggregated at the 
highest levels of the observed Cminss interval. Some patients responded better than patients who 
received higher doses and had higher nivolumab concentrations. 
There was an apparent contradiction between the linear PK of nivolumab, the presence of a correlation 
between dose and ORR and the absence of correlation between concentration and ORR or the 
existence of an E-R correlation but only within a dose range. This result can now be explained by the 
relationship shown between nivolumab clearance and response to treatment [38]. 
The authors concluded that nivolumab was well tolerated up to 10 mg/kg every 2 weeks, and E-R 
relationships for efficacy suggested that nivolumab at 1 mg/kg every 2 weeks could be active for highly 
immunogenic tumours such as melanoma. However, they suggested that a dose of 3 mg/kg every 2 
weeks may be necessary for less immunogenic tumours such as NSCLC. Therefore, 3 mg/kg every 2 
weeks was used as a single dose for nivolumab monotherapy for all tumour types. 
The analysis of the E-R relationship in advanced melanoma has since been performed from exposure 
to nivolumab following first administration [56] (Table 3). This analysis contributed to the authorization 
of nivolumab in the treatment of advanced melanoma since the favourable benefit-risk profile of the 
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proposed dosage was supported by this study. A previously published PK model was applied to patient 
PK data [37]. For exposure-effectiveness analyses, concentrations averaged over time after the first 
administration (Cavg1) were determined for each patient from Bayesian maximum a posteriori 
estimates of individual PK parameters obtained from the PK model. They were calculated by dividing 
the AUC after the first dose by the interval between doses (14 days for administration every two 
weeks). The efficacy criterion was the BOR according to RECIST criteria. Cavg1 was also used as an 
exposure measure to study the E-R relationship with OS and the time before an AE leading to 
discontinuation of treatment or death (AE-DC/D) occurs. 
No correlation was found between Cavg1 and ORR or OS. None of the covariates studied were 
significantly correlated with OR. Significant predictors of OS were nivolumab clearance, baseline 
weight and baseline LDH. A sensitivity analysis excluding clearance from the full model showed that 
the effect of Cavg1 on OS remained non-significant. 37 AE led to treatment discontinuation or patient 
death among the patients treated for advanced melanoma included in the analysis (1 AE leading to 
death). Cavg1 in nivolumab was not significantly correlated with the risk of AE-DC/D. However, the risk 
of AE-DC/D was higher for higher  LDH values at baseline. 
Subsequently, the E-R relationship analysis of Wang et al. [56] was extended to OS in previously 
untreated severe melanoma patients [57] (Table 3). 
No significant effect of Cavg1 on the risk of death was demonstrated. Covariates with significant effect 
on OS were: ECOG status, baseline weight, nivolumab clearance, age, baseline LDH level. The predictor 
associated with the most important effect was clearance of nivolumab. A sensitivity analysis excluding 
clearance from the full model found that Cavg1 was not a significant predictor of OS; the effect 
associated with ECOG status was more important in this analysis, suggesting that the effect of 
clearance is related to disease severity, as observed for pembrolizumab. 
This E-R model was used to propose to the FDA a change in the recommended US dose of nivolumab, 
from 3 mg/kg every two weeks to a fixed dose of 240 mg every two weeks. 
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4.4. Combination of ipilimumab and nivolumab 
The effects of a combination of nivolumab with ipilimumab in a concomitant or a sequential protocol 
were evaluated in a Phase 1 dose-escalation study (NCT01024231) [12] in advanced or metastatic 
melanoma. 53 patients received the concomitant protocol and 33 patients were included in the 
sequential protocol. The results of this trial supported the superiority of the concomitant protocol over 
the sequential protocol. The safety and response profile at the different dose levels studied in the 
concomitant protocol contributed to the selection of nivolumab 1 mg/kg in combination with 
ipilimumab 3 mg/kg. 
Following these results, a randomized controlled phase 2 study (CHECKMATE 069, NCT01927419) 
involving 142 previously untreated metastatic melanoma patients [58] (Postow et al, 2015) compared 
ipilimumab at 3 mg/kg with or without nivolumab at 1 mg/kg every 3 weeks for 4 administrations, 
followed by a maintenance phase with nivolumab at 3 mg/kg or placebo every two weeks until disease 
progression or occurrence of intolerable AE. The primary endpoint was the objective response rate in 
patients with non-mutated tumours for BRAF V600. The comparison showed a significantly higher 
response rate in the arm that combined ipilimumab with nivolumab (61%, 44 of 72 patients) compared 
to the arm in which patients were treated with ipilimumab alone (11%, 4 of 37 patients). The frequency 
of grade 3 or 4 AEs was also higher: 54% in the arm receiving the combination versus 24% in the arm 
alone. 
A Phase 3 randomized controlled trial (CHECKMATE 067, NCT01844505) compared 945 patients with 
advanced non-resectable or metastatic melanoma not previously treated with nivolumab 
monotherapy, nivolumab plus ipilimumab, and ipilimumab monotherapy [59]. The median PFS was 
higher in the dual-therapy group at 11.5 months (95% confidence interval: 8.9 - 16.7) compared to 
nivolumab monotherapy where it was 6.9 months (4.3 - 9.5) and especially compared to ipilimumab 
monotherapy in which the median PFS was 2.9 months (2.8 - 3.4). As in the Postow et al. study, the 
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frequency of grade 3 and 4 AEs was higher with dual therapy compared to ipilimumab monotherapy 
and especially compared to nivolumab monotherapy. 
For patients with PD-L1 tumour expression, there was no difference in survival between nivolumab 
arm or nivolumab plus ipilimumab combination, but for patients without PD-L1 tumour expression, 
the median PFS was prolonged with dual therapy at 11.2 months versus 5.3 months. 
The results of these two trials (CHECKMATE 067 and 069) led to the extension of the approval of 
nivolumab for the treatment of advanced melanoma (non-resectable or metastatic) in combination 
with ipilimumab. 
4.5. Combination of ipilimumab and pembrolizumab 
The results obtained by the combination of ipilimumab and nivolumab motivated the study of the 
association between ipilimumab and pembrolizumab in advanced melanoma. In an open-label Phase 
1b clinical trial (KEYNOTE-029, NCT02089685) [60], 153 patients with advanced melanoma received 
pembrolizumab 2 mg/kg in combination with ipilimumab 1 mg/kg every 3 weeks for 4 administrations 
followed by a maintenance phase of pembrolizumab 2 mg/kg every 3 weeks for 2 years or until disease 
progression or intolerable toxicity. Primary endpoints were therapeutic efficacy quantified by ORR and 
treatment tolerability. OS and PFS were also collected. Early results from this study showed a response 
rate in patients on dual therapy of 61% (95% confidence interval: 53 - 69), comparable to that observed 
with ipilimumab plus nivolumab. Grade 3-4 AEs accounted for 45% of patients. Several randomized 
Phase 2 trials are ongoing to study ipilimumab plus pembrolizumab in combination with different 
dosages. 
5. Fixed dosing 
5.1. Pembrolizumab 
Based on the PK data for pembrolizumab, Merck sought to re-evaluate the need for dosage adjustment 
based on patient weight [52]. The effect of weight on PK described by Ahamadi et al [34] was based 
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on data from the 1622 patients with a wide distribution of body weights, with a median weight of 77.2 
kg over a range of 35.7 to 209.5 kg. 
Patient data from clinical trials where pembrolizumab was administered at a dose adjusted to weight 
(2-10 mg/kg every 2-3 weeks) and trials where pembrolizumab was administered at the fixed dose of 
200 mg every three weeks were used for this analysis. A previously described popPK model [34], based 
on patient data from KEYNOTE-001, 002 and 006, was used to estimate PK parameters and exposures 
from patient specimens and to simulate fixed-dose PK. The PK model parameters were re-estimated 
by incrementing the database with information from ulterior trials. 
A relatively flat exposure-effect relationship was observed in the treatment of melanoma and NSCLC 
in terms of response to tumour size and occurrence of AE. The dose of 2 mg/kg every 3 weeks was 
selected for the treatment of melanoma and NSCLC as sufficient to achieve significant clinical benefit, 
with limited benefit from dose increases. Simulations showed superposition of pembrolizumab 
exposures for doses of 2 mg/kg every 3 weeks and 200 mg fixed dose every 3 weeks. PK data from 
clinical trials conducted at the 200 mg dose every 3 weeks confirmed the results of the simulations. 
More recently, the same strategy has been used to obtain EMA approval for the 400 mg every 6 weeks 
regimen (Table 1). The exposure predicted by the simulations for this new regimen was comparable to 
that obtained with doses of 200 mg every 3 weeks and 2 mg/kg every 3 weeks [61]. A clinical trial at 
this dosage regimen is ongoing to evaluate pembrolizumab as adjuvant therapy in the treatment of 
advanced cutaneous squamous cell carcinoma (KEYNOTE-630). 
5.2. Nivolumab 
A similar approach was implemented by Bristol-Myers Squibb to identify a fixed dose, unrelated to 
patient weight, at which nivolumab should be administered [62]. Body weights from 3458 patients 
included in 18 clinical trials of nivolumab for various tumours such as melanoma, NSCLC, renal 
carcinoma, urothelial carcinoma, gastric cancer and small cell bronchial cancer were used to assess the 
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distribution of patient body weights. The fixed dose was chosen to ensure a significant rate of overlap 
between fixed dose and dose to weight exposures of nivolumab over this body weight range. 
The benefit-risk profile of the fixed dose was evaluated by comparing the exposures obtained with 
those of the 3mg/kg dose every two weeks for the overall weight and tumour type distribution, 
considering the observed safety of use for exposures associated with the 10mg/kg dose every two 
weeks, the observed safety of use at 3 mg/kg every two weeks per body weight group in patients with 
melanoma, NSCLC and renal cell carcinoma, and the results of the E-R safety and efficacy analyses. 
The fixed dose of 240 mg was selected by multiplying the authorized dose of 3 mg/kg every two weeks 
by the median weight of the population tested, about 80 kg. 
This study, based entirely on modelling and simulation, without independent testing in new patients, 
allowed nivolumab to be administered at a dose of 240 mg every 2 weeks in the treatment of 
melanoma, NSCLC, renal cancer and urothelial cancer in the United States. The exposure, safety and 
therapeutic efficacy of fixed-dose nivolumab were considered similar to those observed with the 
previously authorized dose per kg. 
The same strategy based on modelling and simulation of PK data was used to obtain approval for the 
480 mg Q4w regimen [63]. 
6. Discussion 
PK and PKPD studies were at the heart of the development of monoclonal antibodies immune check 
point inhibitors now approved for the treatment of advanced melanoma. The choice of doses at which 
to conduct clinical trials and further the choice of doses at which to use these new therapies were not 
based on the identification of a maximum tolerated dose from dose-escalation studies. Thus the 
strategy of development of immunotherapies differs from that traditionally applied to cytotoxic 
therapies in oncology and PK and PKPD modelling is essential. 
Pharmacokinetic studies of anti-PD1 (Table 2) have shown that their clearance varied over time [36-
38], and that it was correlated with disease progression. The clearance of anti-PD1 decreases as tumor 
Ac
ce
pte
d m
an
us
cri
pt
20 
 
mass decreases. This relationship between clearance and outcome makes the study of exposure-effect 
relationships complex and the mechanism responsible for this relationship is not yet clear. Cachexia 
syndrome frequently associated with advanced cancer diseases has been proposed as one of the 
causes of this phenomenon. In cachexia syndrome, protein catabolism is significantly increased [64] 
which could potentially have an impact on the degradation of therapeutic IgG anti-PD1. The catabolic 
state associated with cachexia may decrease with regression of the disease, which would explain the 
decrease in clearance in patients with reduced tumour mass. However, this hypothesis does not 
explain the time-independent clearance described for ipilimumab [31]. An important cause of 
pharmacokinetic variability of monoclonal antibodies is TMDD [65], which is frequently responsible for 
non-linear pharmacokinetics. The difference in expression between CTLA4, which is only present on 
the surface of activated T cells, and PD1, which is expressed on the surface of a wide range of immune 
cells, has been suggested to explain the time-independent clearance observed with ipilimumab [66]. 
Another element that made the study of exposure-response relationships complex was the selection 
of a relevant endpoint. OS is the criterion that provides the most reliable information, but the median 
OS is achieved late in patients treated with checkpoint inhibitors. Surrogate endpoints such as PFS or 
ORR were used to allow early exposure-response studies to be carried out. It is now known that the 
correlation is poor for immunotherapies in melanoma treatment between OS and PFS (R² = 0.192), as 
well as between OS and ORR (R² = 0.028) [67]. The indirect effect of treatment through immune system 
cells is responsible for atypical responses: delayed responses or even initial progression of the tumour 
mass before the response is obtained. New criteria such as the immune related response criteria (irRC), 
which are better correlated with exposure, have been developed to address the mismatch between 
PFS/ORR and OS [68]. For pembrolizumab, it has been suggested that the evaluation of response 
according to ORR may underestimate the benefit of treatment in about 15% of patients [69] while the 
use of irRC could prevent premature discontinuation of anti-PD1 therapy. However, the correlation 
between irRC and OS remains to be demonstrated. 
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Several aspects remain to be studied regarding these new drugs. A recent Danish study [70] found that 
55% of the population of patients with advanced melanoma eligible for treatment with immune check 
point inhibitors were not included in clinical trials. An ECOG-PS score ≥ 2 or the presence of brain 
metastasis accounted for 74% of the causes of non-eligibility whereas exposure-response studies 
conducted to date have shown a significant impact of the ECOG-PS score on the PK of anti-PD-1. 
Evaluation of the PKPD of immunotherapies in patients treated in the indications covered by marketed 
authorizations would confirm the appropriateness of selected dosages to the heterogeneous 
population actually treated. 
Another point is that some patients eligible for immunotherapies with immune check point inhibitors 
do not respond to treatment. The heterogeneity of responses described by Chatterjee et al. [47] with 
their tumour growth model in advanced melanoma illustrates this well. The causes of these resistances 
to treatment are certainly multiple. Recent studies have highlighted for example the impact of 
digestive microbiota on the probability of therapeutic success of immunotherapies [71].  
Finally, beyond the choice of the right dose for a given population, the thorough elucidation of 
exposure-response relationships could open the way to personalized medicine. The study of 
ipilimumab [42] ER relationships showed the correlation between exposure and OS suggesting that 
ipilimumab TDM would provide the means to achieve the best probability of survival. Indeed, clinical 
trials have shown that weight based dosing was not sufficient to control the PK variability of ipilimumab 
[31]. Two questions will need to be addressed before ipilimumab TDM can be made available to 
patients. First of all, it will be necessary to study the exposure-OS relationship before reaching steady 
state to determine whether early information on blood levels can guide dose selection. Since the 
steady state is only reached after the 4 courses of ipilimumab, it is too late to propose a dose 
adjustment. Secondly, it will be necessary to determine the optimal exposure that maximizes clinical 
efficacy. For pembrolizumab and nivolumab, on the other hand, the flat relationship observed 
between exposure and survival is in favour of higher than needed exposure [53,56,57]. Dose reduction 
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is possible for these anti-PD1 but further studies will be needed to determine the minimum exposure 
required to reach the maximum efficiency plateau.  
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Table 1: Recommended regimens and indications of immune checkpoint immunotherapies authorized for the treatment of melanoma 
Q2W: every two weeks, Q3W: every three weeks, Q4w: every four weeks, Q6w: every six weeks 
  
Immune 
Checkpoint 
Inhibitors 
Therapeutic 
indication 
Weight based 
dosing (EMA) 
Fixed dosing 
(EMA) 
Weight based 
dosing (FDA) 
Fixed dosing (FDA) References 
Ipilimumab Advanced or 
metastatic 
3 mg/kg Q3w (4 
doses) 
 3 mg/kg Q3w (4 
doses) 
 [16] 
 Adjuvant 
treatment 
  10 mg/kg Q3w (4 
doses) followed 
by Q12w for up to 
3 years 
  
 Advanced or 
metastatic, in 
association with 
nivolumab 
3 mg/kg Q3w (4 
doses) 
    
Pembrolizumab Advanced or 
metastatic 
 200 mg Q3w 
400 mg Q6w 
 200 mg Q3w [17] 
 Adjuvant 
treatment 
 200 mg Q3w 
400 mg Q6w 
 200 mg Q3w  
Nivolumab Advanced or 
metastatic 
 240 mg Q2w 
480 mg Q4w 
 240 mg Q2w 
480 mg Q4w 
[18] 
 Adjuvant 
treatment 
3 mg/kg Q2w   240 mg Q2w 
480 mg Q4w 
 
 Advanced or 
metastatic, in 
association with 
ipilimumab 
1 mg/kg Q3w (4 
doses) followed 
by fixed dosing 
monotherapy 
 1 mg/kg Q3w (4 
doses) followed 
by fixed dosing 
monotherapy 
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Table 2: Pharmacokinetic analyses of immune checkpoint immunotherapies for the treatment of melanoma 
Immune 
Checkpoint 
Inhibitors 
References Number 
of 
patients 
Regimens 
studied 
CL (L/day) TDPK Vc (L) Vp (L) Q (L/day) Elimination 
half life (days) 
Studies included 
in the analysis 
Ipilimumab Feng 2014 
[31] 
499 0.3 to 10 
mg/kg 
0.36 no 4.15 3.11 0.986 14.7 CA184‐022, 
CA184‐004, 
CA184‐007, 
CA184‐008 
Pembrolizumab Ahamadi 
2017 [34] 
2195 1 to 10 
mg/kg 
Q2w or Q3w 
0.22 no 3.48 4.06 0.795 27.3 KEYNOTE‐001, 
KEYNOTE‐002, 
KEYNOTE‐006 
 Li 2017 
[36] 
2841 1 to 10 
mg/kg Q2w 
or Q3w 
0.249* yes 3.47 2.96 0.889 NA KEYNOTE‐001, 
KEYNOTE‐002, 
KEYNOTE‐006, 
KEYNOTE‐010 
Nivolumab Bajaj 2017 
a [37] 
1895 0.1 to 10 
mg/kg Q2w 
or Q3w 
0.226 no 3.63 2.78 0.770 25 MDX1106‐01, 
ONO‐4538‐01, 
MDX1106‐03, 
CA209010, 
CA209063, 
CA209010, ONO‐
4538‐02, 
CA209017, 
CA209037, 
CA209025, 
CA209057, 
CA209066 Ac
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 Liu 2017 
[38] 
Idem 
Bajaj 
2017 
Idem Bajaj 
2017 
0.228* yes 3.87 3.01 0.794 NA Idem Bajaj 2017 
CL: clearance, TDPK: time-dependent clearance, Vc: distribution volume of the central compartment, Vp: distribution volume of the peripheral 
compartment, Q: intercompartmental clearance, Q2W: every two weeks, Q3W: every three weeks,  NA: not available 
*initial clearance 
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Table 3: Exposure-response analyses of immune checkpoint immunotherapies for the treatment of melanoma 
Immune 
Checkpoint 
Inhibitors 
Reference
s 
Numbe
r of 
patient
s 
Regimen
s studied 
Exposure  metric 
(pharmacokinetics
) 
OS PFS ORR irRC TGD Studies 
included 
in the 
analysis 
Ipilimumab Wolchok 
2010 [30] 
217 0.3 to 10 
mg/kg 
Q3w 
Dose Positive 
relationshi
p 
    CA184‐
022  
 Feng 2013 
[42] 
498 0.3, 3 
and 10 
mg/kg 
Q3w 
Cminss Positive 
relationshi
p 
 Positive 
relationshi
p 
Positive 
relationshi
p 
 CA184‐
022, 
CA184‐
004, 
CA184‐
007, 
CA184‐
008   
Pembrolizuma
b 
Chatterjee 
2017 [47] 
364 2 or 10 
mg/kg 
Q2w or 
Q3w 
AUCss6w     No 
relationshi
p 
KEYNOTE‐
001, 
KEYNOTE‐
002, 
KEYNOTE‐
006 
 Turner 
2018 [53] 
211 2 or 10 
mg/kg 
Q2w or 
Q3w 
AUC6weeks,CL0 No 
relationshi
p 
    KEYNOTE‐
002, 
KEYNOTE‐
010, 
KEYNOTE‐
024 Ac
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Nivolumab Agrawal 
2016 [54] 
107 0.1 to 10 
mg/kg 
Q2w 
Cminss   Positive 
relationshi
p for doses 
< 1 mg/kg 
 No 
relationshi
p  tumor 
shrinkage 
rate 
 
Negative 
relationshi
p tumour 
progressio
n rate 
MDX1106
‐03 
    Dose  Numericall
y higher at 
3 mg/kg  
No 
relationshi
p 
   
 Wang 
2017 [56] 
221  
 
0.1 to 10 
mg/kg 
Q2w 
Cavg1 
 
No 
relationshi
p 
 No 
relationshi
p 
  CA209003
, 
CA209037 
 Bajaj 2017 
b [57] 
399 0.1 to 10 
mg/kg 
Q2w 
Cavg1  No 
relationshi
p 
    CA209003
, 
CA209037
, 
CA209066 
Q2W: every two weeks, Q3W: every three weeks,  Cminss: steady state minimum concentration, AUCss6w: area under the concentration-time curve 
over 6 weeks at steady state, AUC6weeks,CL0: area under the concentration-time curve over 6 weeks calculated from the clearance of the drug following 
the first administration, Cavg1: concentration averaged over time after the first administration, OOR: overall response rate, OS: overall survival,  PFS: 
progression free survival, irRC: immune-related response criteria, TGD: tumor growth dynamic Ac
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